Thus, it is possible that increased GDF15 expression reflects an aggressive tumor phenotype associated with systemic catabolic effects, which could partly explain the discrepancy between the lower TNM stage and poor prognosis in our cohort. The gene discussed is GDF15; the disease is neoplasm.